Contact information

Dr. med. Kirsten Fischer

German CLL Study Group

Department I of Internal Medicine

University Hospital of Cologne

Kerpener Straße 62 

50937 Cologne


Academic education

1998 - 2004  Medical School, University of Cologne


Scientific degrees

11/2006 MD thesis, Department of Pediatrics, University of Cologne, Advisor:  Prof. Dr. E. Rietschel
06/2004 Graduation from Medical School, University of Cologne


Scientific career

2010 - present Elected steering board member of the German CLL Study Group
2004 - present  Head of Study Office German CLL Study Group
2004 - present  Study Physician at the Department I of Internal Medicine, University Hospital of Cologne


Honors/ Awards/ Memberships

2022 Invited Speaker by The European Hematology Association (EHA): Education Program: Lecture on “Sequencing Therapies in Chronic Lymphocytic Leukemia (CLL)” at the Annual Meeting 2022                          
2021 Member of the program committee, International Workshop on CLL (iwCLL)
2020 Invited Speaker by the American Society of Oncology (ASCO): Education Program: Lecture on “Current Perspectives on Therapy for Chronic Lymphocytic Leukemia (CLL)” at the Annual Meeting 2020
2020 Invited Speaker by the American Society of Hematology (ASH): Education Program: Lecture on “Managing toxicities of targeted therapies in Chronic Lymphocytic Leukemia (CLL) at the Annual Meeting 2020
2019 European Hematology Association (EHA): Presidential Symposium: Presentation of best abstract “Fixed-duration venetoclax plus obinutuzumab improves  progression-free survival and minimal residual disease negativity in patients with previously untreated Chronic Lymphocytic Leukemia (CLL) and comorbidities (S149)” at the 24th Congress of the European Hematology Association
2017 Invited Speaker by the American Society of Hematology (ASH): Education Program: Lecture on  “Optimizing frontline therapy of untreated Chronic Lymphocytic Leukemia (CLL) based on clinical and biological factors” at the Annual Meeting 2017
2015 Reviewer, European Hematology Association (EHA)
2014 Reviewer, American Society of Oncology (ASH)
2010 - 2014 Co-chair Young Investigators´ Meeting on CLL


  • Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

    Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited. In this open-label parallel-group phase-3 study, 432 patients with previously untreated CLL were randomized…

  • First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

    BACKGROUND Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. METHODS In a phase 3, open-label trial, we randomly assigned,…

  • Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

    In patients with chronic lymphocytic leukemia, Richter transformation (RT) reflects the development of an aggressive lymphoma that is associated with poor response to chemotherapy and short survival. We initiated an international, investigator-initiated, prospective, open-label phase 2 study in…

  • Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known. In this open-label, phase 3 trial, we investigated fixed-duration treatment with…

  • Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia

    For several decades, allogeneic hematopoietic stem cell transplantation (alloHCT) has been a therapeutic option in patients with chronic lymphocytic leukemia (CLL) with high-risk features such as del(17p) and/or TP53 mutations, complex aberrant karyotype, or chemotherapy-resistant disease. With the…

  • High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

  • The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia

    The scaffold protein NEDD9 is frequently upregulated and hyperphosphorylated in cancers, and is associated with poor clinical outcome. NEDD9 promotes B-cell adhesion, migration and chemotaxis, pivotal processes for malignant development. We show that global or B-cell-specific deletion of Nedd9 in…

  • Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

  • Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials

    Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the…

  • Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia

  • MARCKS affects cell motility and response to BTK inhibitors in CLL

    Bruton tyrosine kinase (BTK) inhibitors are highly active drugs for the treatment of chronic lymphocytic leukemia (CLL). To understand the response to BTK inhibitors on a molecular level, we performed (phospho)proteomic analyses under ibrutinib treatment. We identified 3466 proteins and 9184…

  • Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

    The CLL14 study has established one-year fixed-duration treatment of venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic lymphocytic leukemia. With all patients off treatment for at least three years, we report a detailed analysis of minimal residual disease (MRD)…